Screener / SEC EDGAR /CIK 0001014739 /10-K filed Feb 24, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Home Health Care Services

Option Care Health, Inc. OPCH

Compare with peers Embed
New in the 10-K 9 paragraphs with nothing like them in the 10-K filed Feb 26, 2025 New in the 10-Q 36 paragraphs not in the 10-Q filed Jul 29, 2026 10-Q against the 10-K 21 risk factor paragraphs and sentences added or reworded

New risk paragraphs, branching off last year

Each branch is a paragraph in Risk Factors with nothing like it in the 10-K filed Feb 26, 2025. A box jumps to the paragraph as filed, below.

9 new

Paragraphs with nothing like them in last year's 10-K

Quoted exactly

9 paragraphs in Risk Factors of the 10-K filed Feb 24, 2026 with nothing like them in the 10-K filed Feb 26, 2025. Quoted exactly. Paragraphs that were only edited are under 10-K change.

Increasing competition from established and vertically integrated healthcare providers, coupled with industry consolidation and cost pressures, may limit our ability to grow revenue, maintain pricing, secure favorable contracts, and access critical pharmaceutical products.

Read in the 10-K

Contracts and fee schedules for prescription drug reimbursement, including our contracts with commercial payers, PBMs, and Medicaid programs, generally use certain published benchmarks to establish pricing. These benchmarks include Average Wholesale Price (“AWP”), Wholesale Acquisition price (“WAC”), Average Selling Price (“ASP”), among others. Future changes to the use of AWP, WAC, ASP or other public pricing benchmarks used to establish drug pricing, including changes in reimbursement calculations by federal and state healthcare programs, could impact our reimbursement and our ability to negotiate rebates and/or discounts with drug manufacturers and wholesalers.

Read in the 10-K

Our business could be adversely affected if we fail to effectively adopt and integrate evolving technologies such as artificial intelligence (“AI”), attract and retain necessary technical talent, or adapt to competitive, technological, or structural changes in the healthcare products and services industry, any of which could impair our ability to attract and retain clients and maintain our competitive position.

Read in the 10-K

Ongoing reimbursement rate reductions, pricing pressures from Third-Party Payers and managed care payers, and increasing payer consolidation could significantly impact revenue, reduce profitability, and concentrate financial dependence on a few large payers.

Read in the 10-K

Regulatory changes, increased scrutiny, or reclassification of our compounding practices as an FDA-regulated outsourcing facility could lead to costly compliance requirements, operational disruptions, and reputational harm.

Read in the 10-K
Show the other 4

Pursuing acquisitions or strategic investments and alliances may expose us to integration challenges, valuation uncertainties, operational disruptions, and potential financial losses if these investments fail to deliver expected benefits.

Read in the 10-K

Reliance on third-party hosting services exposes us to potential security breaches, service disruptions, and pricing changes that could negatively impact operations and financial performance.

Read in the 10-K

The development and use of AI technologies could expose us to significant governance, compliance, and legal liabilities, including evolving regulatory requirements, heightened scrutiny, litigation risk, and substantial compliance costs, that may adversely affect our operations, financial condition, and ability to successfully adopt and deploy AI.

Read in the 10-K

Acts of God, such as major weather disturbances or other force majeure events, could disrupt our business.

Read in the 10-K

Paragraphs in the 10-Q filed Nov 4, 2026 that were not in the one before

New in the latest 10-Q

36 paragraphs in the 10-Q filed Nov 4, 2026 with nothing like them in the 10-Q filed Jul 29, 2026 (at least half the words must differ; new numbers alone do not count). Quoted exactly, grouped by the item heading above them. This is text that changed, not a judgement of how serious it is.

Financial statements and notes

On October 5, 2026, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Onyx Bidco LLC (“Parent”) and Onyx Merger Sub, Inc., a wholly owned subsidiary of Parent, pursuant to which the Company is to be acquired by an investor group comprised of certain affiliates of Clayton, Dubilier & Rice, LLC (“CD&R”) and McKesson Corporation (“McKesson” and such group collectively, the “Investor Group”). Under the terms of the Merger Agreement, each outstanding share of the Company's common stock, subject to certain exceptions specified in the Merger Agreement, will be converted into the right to receive $ 32.05 in cash per share. Upon consummation of the Merger, the Company will become a privately held company, and its common stock will no longer be listed on any public market.

Read in the 10-Q

The Merger is subject to customary closing conditions, including approval by the Company's stockholders and receipt of required regulatory approvals. The Merger is expected to close during the first half of calendar year 2027.

Read in the 10-Q

On October 5, 2026, the Company entered into the Merger Agreement with Parent and Merger Sub, pursuant to which the Company is to be acquired by the Investor Group. Pursuant to the Merger Agreement, Merger Sub will be merged with and into the Company (the “Merger”), with the Company continuing as the surviving corporation of the Merger and as a wholly owned subsidiary of Parent.

Read in the 10-Q

Upon the terms and subject to the conditions set forth in the Merger Agreement, at the effective time of the Merger (the “Effective Time”), each share of the Company’s common stock that is issued and outstanding as of immediately prior to the Effective Time (other than shares held by the Company as treasury stock, owned by Parent or any of its subsidiaries, including Merger Sub, or as to which appraisal rights have been properly exercised in accordance with Delaware law) will be automatically cancelled, extinguished and converted into the right to receive cash in an amount equal to $32.05 without interest.

Read in the 10-Q

The Merger is expected to close in the first half of calendar year 2027, subject to the satisfaction or waiver of certain conditions. Additional conditions include, without limitation, the accuracy of specified representations and warranties (subject to specified materiality standards), performance of covenants in all material respects and the absence of a Company Material Adverse Effect (as defined in the Merger Agreement) since the date of the Merger Agreement.

Read in the 10-Q
Show the other 31

The Merger Agreement contains specified termination rights for the Company and Parent, including in the event that the Merger has not been consummated on or prior to 11:59 p.m., New York City time, on October 5, 2027. Additionally, the Merger Agreement requires the Company to pay Parent a termination fee of approximately $145.96 million if the Merger Agreement is terminated under certain circumstances. The Merger Agreement also requires Parent to pay the Company a reverse termination fee of approximately $291.93 million if the Merger Agreement is terminated under certain circumstances.

Read in the 10-Q

Upon consummation of the Merger, the Company will become a privately held company, and its common stock will no longer be listed on any public market.

Read in the 10-Q

Three Months Ended September 30, 2026 Compared to Three Months Ended September 30, 2025

Read in the 10-Q

The increase in selling, general and administrative expenses during the three months ended September 30, 2026 was primarily attributable to transaction costs related to the pending Merger.

Read in the 10-Q

Nine Months Ended September 30, 2026 Compared to Nine Months Ended September 30, 2025

Read in the 10-Q

Our business strategy includes strategic deployment of capital to internal investments in resources, infrastructure, and technologies to support future growth and the pursuit of strategic tuck-in and adjacent acquisitions that complement our existing operations. However, while the Merger is pending, our capital deployment and acquisition activities are subject to the terms of the Merger Agreement, which restrict, among other things, certain acquisitions, capital expenditures and financing activities, subject to specified exceptions or the prior written consent of Parent. These restrictions may limit or delay our ability to pursue acquisition opportunities and other strategic investments during the periods prior to the completion of the Merger.

Read in the 10-Q

Nine Months Ended September 30, 2026 Compared to Nine Months Ended September 30, 2025

Read in the 10-Q

Risk Factors

Uncertainties associated with the Merger could adversely affect our business, financial condition and results of operations, and the trading price of our common stock.

Read in the 10-Q

On October 5, 2026, the Company entered into the Merger Agreement with Parent and Merger Sub pursuant to which the Company is to be acquired by the Investor Group. Completion of the Merger is subject to various customary closing conditions and regulatory approvals, including (i) the adoption of the Merger Agreement by the affirmative vote of the holders of a majority of the issued and outstanding shares of the Company’s common stock entitled to vote at a special meeting of the Company’s stockholders; (ii) the expiration or termination of the applicable waiting period under the HSR Act; (iii) the expiration or termination of applicable waiting periods under specified healthcare regulatory filings and the receipt and continued effectiveness of consents, authorizations and approvals, including certain state healthcare regulatory approvals; and (iv) the absence of any law, injunction or order prohibiting, enjoining or otherwise making illegal the consummation of the Merger. The parties to the Merger Agreement may not receive the necessary approvals for the transaction or may not receive them within the expected timeframe. The failure to satisfy these and other closing conditions could jeopardize, delay or prevent the consummation of the Merger.

Read in the 10-Q

The pendency of the Merger, as well as any delays in the expected timeframe, could cause disruption to our ongoing operations and create uncertainties, any of which could have an adverse effect on our business, results of operations, financial condition and the trading price of our common stock, regardless of whether the Merger is completed. These risks include, but are not limited to:

Read in the 10-Q

• risks related to the diversion of management’s attention from ongoing business operations due to the pending Merger;

Read in the 10-Q

• changes or loss in our relationships with our employees, patients, referral sources, payors, customers, suppliers, distributors and other business partners;

Read in the 10-Q

• being subject to certain restrictions on the conduct of our business unless approved by Parent in writing (which approval may not be unreasonably withheld, conditioned or delayed);

Read in the 10-Q

• possibly foregoing certain business opportunities that we might otherwise pursue absent the Merger; and

Read in the 10-Q

The adverse effects of the pendency of the Merger could be exacerbated by any delays in completion of the Merger or by termination of the Merger Agreement. Even if successfully completed, there are certain risks to our stockholders from the Merger, including:

Read in the 10-Q

• the per-share price is fixed and will not be adjusted for changes in our business, assets, liabilities, prospects, outlook, financial condition or results of operations, or in the event of any change in the market price of, analyst estimates of, or projections relating to our common stock;

Read in the 10-Q

• the fact that the exchange of common stock for cash pursuant to the Merger will be a taxable transaction for U.S. federal income tax purposes; and

Read in the 10-Q

• the fact that, if the Merger is completed, our stockholders will not participate in any future growth potential or benefit from any future increase in our value.

Read in the 10-Q

Failure to complete the Merger could adversely affect our business and the price of our shares of common stock.

Read in the 10-Q

The closing of the Merger may not occur on the expected timeline or at all. The Merger Agreement contains certain customary termination rights for us and Parent, including, among others: (i) if the Merger is not consummated on or before October 5, 2027; (ii) if the requisite stockholder approval is not obtained at a meeting of Company stockholders (or any adjournment or postponement thereof) at which a vote is taken on the Merger; (iii) if the other party breaches its representations, warranties, covenants or other agreements in the Merger Agreement in a manner that would cause the conditions to the closing of the Merger to not be satisfied and fails to cure such breach within the applicable cure period; (iv) if any law, order or judgment permanently prohibiting the Merger has become final and non-appealable; or (v) by mutual written agreement of Parent and the Company. If the Merger Agreement is terminated and the Merger is not consummated, the price of our common stock may decline, we may experience negative reactions from the financial markets, including adverse stock price impacts, or from our vendors, customers and other business partners, and you may not recover your investment or receive a price for your shares of common stock similar to what has been offered as a result of the Merger.

Read in the 10-Q

If the Merger Agreement is terminated under certain circumstances set forth in the Merger Agreement, including as a result of the Company’s entry into a definitive agreement related to an alternative business combination transaction providing for a Superior Proposal (as defined in the Merger Agreement), the Company will be required to pay Parent a termination fee of approximately $145.96 million. If the Company is required to pay the termination fee, such fee, together with costs incurred to negotiate the Merger Agreement and pursue the Merger, could have a material adverse effect on the Company’s liquidity, financial condition and results of operations.

Read in the 10-Q

In addition, if Parent fails to fund the equity financing or close on the debt financing contemplated by the Merger Agreement and thereby fails to have sufficient funds to consummate the Merger, we may be forced to pursue costly litigation to obtain payment of the termination fee that Parent would be required to pay us in that circumstance or pursue specific performance of the Merger Agreement to compel Parent to close, and we may be unable to obtain adequate relief.

Read in the 10-Q

The Merger Agreement contains provisions that limit our ability to pursue alternatives to the Merger.

Read in the 10-Q

Under the Merger Agreement, we are generally prohibited from, among other things, soliciting, initiating or knowingly encouraging alternative acquisition proposals, providing non-public information to, or engaging in discussions or negotiations with, third parties regarding alternative acquisition proposals, and entering into any alternative acquisition agreement, except in limited circumstances to comply with our fiduciary duties. As described above, we may also be required to pay a termination fee if the Merger Agreement is terminated in specified circumstances, including if we terminate the Merger Agreement to pursue an alternative transaction to the Merger. These provisions could discourage a third party that may otherwise have an interest in acquiring all or a significant part of our business from considering or proposing an acquisition, even if such third party were prepared to pay consideration with a higher value than that provided for in the Merger Agreement.

Read in the 10-Q

We are subject to certain restrictions on the conduct of our business under the terms of the Merger Agreement.

Read in the 10-Q

Under the terms of the Merger Agreement, we have agreed to certain restrictions on the operations of our business until the earlier of the consummation of the Merger and the termination of the Merger Agreement. We have agreed to use commercially reasonable efforts to conduct our business in all material respects in the ordinary course of business and to preserve intact in all material respects our business and operations and our relationships with governmental authorities, customers, suppliers, payors, employees and other significant commercial relationships. In addition, subject to certain exceptions, unless approved by Parent in writing (which approval may not be unreasonably withheld, conditioned or delayed), we have agreed to refrain from, among other things: incurring certain debt; entering into, amending, modifying or terminating certain material contracts; selling or transferring rights in material real property; establishing, adopting, entering into or modifying Company employee benefit plans that would materially increase our costs; increasing the compensation or benefits of certain current or former directors, officers, employees and other individual service providers; paying dividends or other distributions; making certain acquisitions; repurchasing shares of our capital stock; settling certain legal proceedings; materially changing our methods, principles or practices of financial accounting; and incurring capital expenditures above specified amounts. Because of these restrictions, we may be prevented from undertaking certain actions with respect to the conduct of our business that we might otherwise have taken if not for the Merger Agreement.

Read in the 10-Q

We and our directors may be subject to litigation challenging the Merger, and an unfavorable judgment or ruling in any such lawsuit could prevent or delay the consummation of the Merger and/or result in substantial costs.

Read in the 10-Q

Putative stockholder complaints, including stockholder class action complaints and other demands that may be made against us or complaints that may be filed against us, the Company’s Board of Directors, parties involved in the Merger and others in connection with the transactions contemplated by the Merger Agreement, may delay or prevent the consummation of the Merger. The outcome of any such demands and complaints or any litigation is uncertain, and we may not be successful in

Read in the 10-Q

defending against these claims. Whether or not any claims are successful, these types of demands and litigation could delay or prevent the Merger, divert the attention of our management and employees from our day-to-day business, and otherwise adversely affect our business, financial condition and results of operations. Additionally, if a plaintiff is successful in obtaining an injunction prohibiting completion of the Merger, then that injunction may delay or prevent the Merger from being completed, which may exacerbate the other risks described herein and adversely affect our business, financial condition and results of operations.

Read in the 10-Q

Share sales and buybacks

As of September 30, 2026, approximately $525.0 millon remained available under the program. Under the terms of the Merger Agreement, during the period from the execution of the Merger Agreement until the earlier of the effective time of the Merger or termination of the Merger Agreement, the Company is not permitted to redeem, repurchase or otherwise acquire any of its capital stock or other equity or voting interests without the prior written consent of Parent (which consent may not be unreasonably withheld, conditioned or delayed), subject to customary exceptions.

Read in the 10-Q

Item 6

*Schedules and exhibits have been omitted pursuant to Item 601(a)(5) and Item 601(b)(2)(ii) of Regulation S-K. The Company agrees to furnish supplemental copies of any of the omitted schedules and exhibits upon request by the SEC.

Read in the 10-Q

The 10-Q's risk factors against the 10-K

Item 1A of the 10-Q filed Nov 4, 2026 against Item 1A of the 10-K filed Feb 24, 2026. A 10-Q repeats only the risks that changed, so a 10-K paragraph that is missing from it is not counted as removed. Added is a paragraph with nothing like it in the 10-K, Reworded a sentence that is in both with several words changed, Quiet changes a sentence in both where one to four words changed and one is a hedge or a modal (cut words struck through, new words highlighted). Text on the page, not a score; each links to the filing at sec.gov.

What the 10-Q itself says about its risk factors:This Form 10-Q should be read in conjunction with the risk factors included in our Form 10-K. Except as set forth below, there have been no material changes to the risk factors affecting our business, financial condition or results of operations from those set forth in Part I, Item 1A. “Risk Factors” in our Form 10-K. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition and/or results of operations.

Read in the 10-Q
Added10-Q Nov 4, 2026 vs 10-K Feb 24, 2026
Uncertainties associated with the Merger could adversely affect our business, financial condition and results of operations, and the trading price of our common stock.

Read it in the 10-Q at sec.gov

Added10-Q Nov 4, 2026 vs 10-K Feb 24, 2026
On October 5, 2026, the Company entered into the Merger Agreement with Parent and Merger Sub pursuant to which the Company is to be acquired by the Investor Group. Completion of the Merger is subject to various customary closing conditions and regulatory approvals, including (i) the adoption of the Merger Agreement by the affirmative vote of the holders of a majority of the issued and outstanding shares of the Company’s common stock entitled to vote at a special meeting of the Company’s stockholders; (ii) the expiration or termination of the applicable waiting period under the HSR Act; (iii) the expiration or termination of applicable waiting periods under specified healthcare regulatory filings and the receipt and continued effectiveness of consents, authorizations and approvals, including certain state healthcare regulatory approvals; and (iv) the absence of any law, injunction or order prohibiting, enjoining or otherwise making illegal the consummation of the Merger. The parties to the Merger Agreement may not receive the necessary approvals for the transaction or may not receive them within the expected timeframe. The failure to satisfy these and other closing conditions could jeopardize, delay or prevent the consummation of the Merger.

Read it in the 10-Q at sec.gov

Added10-Q Nov 4, 2026 vs 10-K Feb 24, 2026
The pendency of the Merger, as well as any delays in the expected timeframe, could cause disruption to our ongoing operations and create uncertainties, any of which could have an adverse effect on our business, results of operations, financial condition and the trading price of our common stock, regardless of whether the Merger is completed. These risks include, but are not limited to:

Read it in the 10-Q at sec.gov

Added10-Q Nov 4, 2026 vs 10-K Feb 24, 2026
• risks related to the diversion of management’s attention from ongoing business operations due to the pending Merger;

Read it in the 10-Q at sec.gov

Added10-Q Nov 4, 2026 vs 10-K Feb 24, 2026
• changes or loss in our relationships with our employees, patients, referral sources, payors, customers, suppliers, distributors and other business partners;

Read it in the 10-Q at sec.gov

Show the other 7
Added10-Q Nov 4, 2026 vs 10-K Feb 24, 2026
• being subject to certain restrictions on the conduct of our business unless approved by Parent in writing (which approval may not be unreasonably withheld, conditioned or delayed);

Read it in the 10-Q at sec.gov

Added10-Q Nov 4, 2026 vs 10-K Feb 24, 2026
The adverse effects of the pendency of the Merger could be exacerbated by any delays in completion of the Merger or by termination of the Merger Agreement. Even if successfully completed, there are certain risks to our stockholders from the Merger, including:

Read it in the 10-Q at sec.gov

Added10-Q Nov 4, 2026 vs 10-K Feb 24, 2026
• the per-share price is fixed and will not be adjusted for changes in our business, assets, liabilities, prospects, outlook, financial condition or results of operations, or in the event of any change in the market price of, analyst estimates of, or projections relating to our common stock;

Read it in the 10-Q at sec.gov

Added10-Q Nov 4, 2026 vs 10-K Feb 24, 2026
• the fact that the exchange of common stock for cash pursuant to the Merger will be a taxable transaction for U.S. federal income tax purposes; and

Read it in the 10-Q at sec.gov

Added10-Q Nov 4, 2026 vs 10-K Feb 24, 2026
• the fact that, if the Merger is completed, our stockholders will not participate in any future growth potential or benefit from any future increase in our value.

Read it in the 10-Q at sec.gov

Added10-Q Nov 4, 2026 vs 10-K Feb 24, 2026
The closing of the Merger may not occur on the expected timeline or at all. The Merger Agreement contains certain customary termination rights for us and Parent, including, among others: (i) if the Merger is not consummated on or before October 5, 2027; (ii) if the requisite stockholder approval is not obtained at a meeting of Company stockholders (or any adjournment or postponement thereof) at which a vote is taken on the Merger; (iii) if the other party breaches its representations, warranties, covenants or other agreements in the Merger Agreement in a manner that would cause the conditions to the closing of the Merger to not be satisfied and fails to cure such breach within the applicable cure period; (iv) if any law, order or judgment permanently prohibiting the Merger has become final and non-appealable; or (v) by mutual written agreement of Parent and the Company. If the Merger Agreement is terminated and the Merger is not consummated, the price of our common stock may decline, we may experience negative reactions from the financial markets, including adverse stock price impacts, or from our vendors, customers and other business partners, and you may not recover your investment or receive a price for your shares of common stock similar to what has been offered as a result of the Merger.

Read it in the 10-Q at sec.gov

The first 12 of 21 are shown (at most 12 of each type).

Phrases used for the first time

Two-word phrases in Risk Factors of the 10-K filed Feb 24, 2026 that are in none of the 1 earlier 10-Ks stored, back to Feb 26, 2025

operational disruptions ×2
Where each one is used
  • operational disruptions: Regulatory changes, increased scrutiny, or reclassification of our compounding practices as an FDA-regulated outsourcing facility could lead to costly compliance requirements, operational disruptions, and reputational harm.

The 10-K at sec.gov

Used at least twice, small words left out. Counted, not picked: a phrase can be new because the company renamed something.

What was taken out

9 paragraphs of last year's Risk Factors with nothing like them now. The longest are quoted.

Across all companies
Our contracts generally use certain published benchmarks to establish pricing for the reimbursement of prescription medications we dispense. These benchmarks include AWP, wholesale acquisition cost, ASP and average manufacturer price. Many of our contracts utilize the AWP benchmark. Publication of the AWP benchmark was expected to cease in 2011 as a result of the settlement of class-action lawsuits brought against First Databank and Medi-Span, third-party publishers of various pricing benchmarks. However, Medi-Span continues to publish the AWP benchmark and has indicated that it will...
In the 10-K filed Feb 26, 2025
Our third amended and restated certificate of incorporation authorizes us to issue one or more series of preferred stock. Our Board of Directors has the authority to determine the preferences, limitations and relative rights of the shares of preferred stock and to fix the number of shares constituting any series and the designation of such series, without any further vote or action by our stockholders. Our preferred stock could be issued with voting, liquidation, dividend and other rights superior to the rights of our common stock. The potential issuance of preferred stock may delay or...
In the 10-K filed Feb 26, 2025
We may issue shares of preferred stock in the future, which could make it difficult for another company to acquire us or could otherwise adversely affect holders of our common stock, which could depress the price of our common stock.
In the 10-K filed Feb 26, 2025
We use, and may continue to expand our use of, machine learning and artificial intelligence (“AI”) technologies to deliver our services and operate our business.
In the 10-K filed Feb 26, 2025

Sources

Item 1A of each 10-K and 10-Q on EDGAR, quoted exactly. Each paragraph links to the filing at sec.gov.

Also

10-K change: what was reworded or cut, section by section.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/OPCH/export.csv") into a cell.

Next:10-K change
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.